IDentif.AI: Artificial Intelligence Pinpoints Remdesivir in Combination with Ritonavir and Lopinavir as an Optimal Regimen Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

CSI Principal Investigator, A/Professor Edward Chow was recently involved in an impactful study led by Professor Dean Ho. The team reported the use of Identif.AI, a platform that rapidly optimizes infectious disease (ID) combination therapy design using artificial intelligence. In the study, IDentif.AI was implemented on a 12-drug candidate therapy search set representing over 530,000 possible drug combinations. Results revealed that the optimal combination therapy against SARS-CoV-2 was comprised of remdesivir, ritonavir, and lopinavir, which mediated a 6.5-fold improvement in efficacy over remdesivir alone. The platform was able to identify clinically actionable optimal drug combination within two weeks, with a 3-order of magnitude reduction in the number of tests typically needed. In addition, Identif.AI was also able to independently confirm clinical trial outcomes to date without requiring any data from these trials. The robustness of Identif.AI opens up avenues for the development of effective treatment options for the current and future outbreaks.

Read more about the study here!